DIA Europe is more than a traditional meeting. It’s a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders.
British drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
https://european-biotechnology.com/wp-content/uploads/2024/04/AZ-123rf__Maksim_Kuzubov_87089413_s.jpg519923Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-12-10 08:01:462018-12-10 08:01:46AZ checkpoint blocker combo fails in head and neck cancer
BioEcho Life Sciences develops novel kits for the isolation and processing of DNA and RNA. The new EchoCLEAN CleanUp kits for rapid single-step purification of RNA or DNA samples with removal of any residual denaturating salts or organic solvents increase the reliability in PCR and NGS analysis.
https://european-biotechnology.com/wp-content/uploads/2024/04/angina-pectoris-presentation-10-728.jpg591810Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-12-06 08:38:002018-12-06 08:38:00XyloCor Therapeutics bags US$17m in Series A financing
For two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number of participants.
Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
https://european-biotechnology.com/wp-content/uploads/2024/04/breast_cancer_18071354_s.jpg599799Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-12-05 08:07:482018-12-05 08:07:48Uncommon mutations affect breast cancer prognosis
GlaxoSmithKline said it will pay $75 per share in cash to take over US oncology player Tesaro, whose FDA-approved DNA repair blocker nirparib (Zejula) made only US$166m in sales in Q1-3/2018.
Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2018_app_carloincerti.png310310h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-12-03 07:57:022018-12-03 07:57:02Forbion appoints Dr. Carlo Incerti as Operating Partner
Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.
DIA Europe 2019: Why attend?
Sponsored PublicationsDIA Europe is more than a traditional meeting. It’s a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders.
AZ checkpoint blocker combo fails in head and neck cancer
Latest NewsBritish drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
Phenol, guanidinium and ethanol affect PCR or NGS analysis
Sponsored PublicationsBioEcho Life Sciences develops novel kits for the isolation and processing of DNA and RNA. The new EchoCLEAN CleanUp kits for rapid single-step purification of RNA or DNA samples with removal of any residual denaturating salts or organic solvents increase the reliability in PCR and NGS analysis.
XyloCor Therapeutics bags US$17m in Series A financing
Latest NewsLSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
BioFIT: innovation and investors
Latest NewsFor two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number of participants.
Uncommon mutations affect breast cancer prognosis
Latest NewsUncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
GSK swallows Tesaro in US$5.1bn deal
Latest NewsGlaxoSmithKline said it will pay $75 per share in cash to take over US oncology player Tesaro, whose FDA-approved DNA repair blocker nirparib (Zejula) made only US$166m in sales in Q1-3/2018.
Argenx in US$1.6bn deal with J&J affiliate Janssen
Latest NewsJanssen affiliate Cilag GmbH International has licenced argenx’ anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Forbion appoints Dr. Carlo Incerti as Operating Partner
AppointmentsForbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.
Driver of GVHD after blood stem cell transplantation identified
Latest NewsSwiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.